Additional European Equity News
Accor (AC FP) - Q1 2026 (EUR): Revenue 1.31bln (prev. 1.34bln Y/Y), Management & Franchise revenue 332mln (prev. 322mln Y/Y), RevPAR +5.1% Y/Y, Net unit growth +3.8% Y/Y. Revenue +2.3% at constant currency driven by PM&E growth (+4.6% cc) offset by L&L decline (-0.7% cc), resilient demand outside Middle East with pricing supporting RevPAR growth. (Accor)
Casino (CA FP) - Financial structure talks continue; agreement targeted by the end of June 2026. (Casino)
Evotec (EVT GY) - CFO Paul Hitchin to step down; effective Apr 30. Co. has named Claire Hinshelwood as the new CFO. (Evotec)
Groupe SEB (SK FP) - Q1 2026 (EUR): Revenue 1.89bln (exp. 1.89bln); LFL +2.7% Y/Y. (Groupe SEB)
Holcim (HOLN SW) - Q1 2026 (CHF): Net sales 3.520bln (prev. 3.696bln Y/Y), Recurring EBITDA 695mln (prev. 758mln Y/Y), Recurring EBIT 431mln (prev. 485mln Y/Y). Recurring EBIT margin 12.2% (prev. 13.1% Y/Y, -90bps); organic net sales +3.9%, organic recurring EBIT +8.3%, FY guidance confirmed. (Holcim)
Sanofi (SAN FP) - Gujarat Themis Biosyn to acquire 13 anti-TB and anti-infective brands from Sanofi for EUR 158mln; to close by Dec'2026. (NDTV)
Spie (SPIE FP) - Q1 (EUR): Revenue 2.45bln (prev. 2.42bln Y/Y). Affirms guidance. (Spie)
Saint Gobain (SGO FP) - Q1 (EUR): Revenue 11.1bln (exp. 11bln). LFL -2.3% Y/Y. Affirms outlook. (Saint Gobain)
Mondi (MNDI LN) - Q1 2026 (EUR): Underlying EBITDA 212mln (prev. 290mln Y/Y, 214mln Q/Q), Forestry fair value gain 8mln (prev. 2mln Y/Y). Sales volumes increased sequentially, offset by lower average selling prices and higher energy, raw material and logistics costs; pricing actions expected to take full effect in Q3. Conditions remain challenging. (Mondi)
Yara International (YAR NO) - Q1 2026 (USD): Revenue 4.259bln (exp. 3.99bln, prev. 3.648bln Y/Y), EBITDA 908mln (prev. 566mln Y/Y), Adj. EBITDA excl. special items 896mln (exp. 812.9mln, prev. 638mln Y/Y), Net income 327mln (prev. 295mln Y/Y), Adj. EPS 1.64 (prev. 1.01 Y/Y). (Yara International)
Capgemini (CAP FP) downgraded to Neutral from Buy at UBS
British American Tobacco (BATS LN) upgraded to Overweight from Underweight at Morgan Stanley
Imperial Brands (IMB LN) downgraded to Equal Weight from Overweight at Morgan Stanley
Neste (NESTE FH) upgraded to Buy from Neutral at UBS
Roche (ROP SW) upgraded to Equal Weight from Underweight at Morgan Stanley